Arthritis news. Anytime. Anywhere.

Hat’s off to surgeon and innovator Cy Frank

The recent passing of surgeon and innovator Cy Frank cast a grey shadow over Canada’s health care community. Dr. Frank was the President and CEO of Alberta Innovates Health Solutions (AIHS), which funds research and promotes innovation in the health system. On March 5, he died in his sleep of a heart attack, at the age of 65.

In an interview with the Globe and Mail, Tom Noseworthy, associate chief medical officer for clinical networks and clinical care pathways at Alberta Health Services, said: “Cy was a visionary leader with a constant, unrelenting commitment to the greater good. It was his preoccupation – obsession even – to make the health system better, and he did.”

Dr. Cyril Frank

Picture from the University of Calgary

Continue reading

Let BC PharmaCare hear “Your Voice” on apremilast for plaque psoriasis

Cartoon man with arrowLet BC PharmaCare hear “Your Voice” on apremilast for plaque psoriasis 

BC PharmaCare is looking for your input on apremilast for the treatment of moderate to severe plaque psoriasis 

Taken orally, apremilast (Otezla®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about apremilast for the treatment of moderate to severe plaque psoriasis.

You can give input if you are a B.C. resident and have plaque psoriasis (with or without psoriatic arthritis), a caregiver to someone with plaque psoriasis, or if your group represents people who live with plaque psorisais.  Continue reading

Online survey: Share YOUR thoughts about a new app to help you be more active

ICON ImageOnline survey: Share YOUR thoughts about a new app to help you be more active

Did you know that walking 10 blocks a day can help improve cognitive health and may even be good for joint health in the long term?

Canadian health consumers like you are developing a new app, called Walk 10 Blocks, that will help you and your friends become more physically active in your neighbourhood, and even make it fun! Continue reading

We miss you already, Dr. Cyril Frank

Dear ABN readers,
Yesterday, our community, and all of Canadian health care, lost a giant in Dr. Cyril Frank.
Cy was a hero to many. His surgical skills and bedside manner restored his patients’ lives. He gave each and every one unparalleled care and years of renewed happiness and quality of life.
Dr. Cyril Frank

Picture from the University of Calgary

To his colleagues, Cy was regarded as nothing short of brilliant. His thoughtful, innovative approach to reform Canadian health care was both effective and inspiring. No challenge was too big for Cy, and he encouraged others to think that way, too. He was strategic, inclusive, kind and funny.

Most important to informed consumers/patients volunteers was his willingness to champion our inclusion at decision-making tables in research and at government. He believed to his core that the patient voice and experience must help drive, along with clinical and scientific expertise, the innovation required to improve the Canadian health care system

We miss you already, Cy.

Call for patient organization input on denosumab for osteoporosis in men

Businessman with a laptopDo you have osteoporosis or care for someone who does? If so, we need your valuable input.

The Common Drug Review (CDR) is now welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for denosumab (the medication’s generic name) for the treatment of osteoporosis in men. This medication has been approved for use by Health Canada for women with postmenopausal osteoporosis with clinical or radiographically-documented fracture due to osteoporosis. Denosumab is an anti-resorptive therapy that inhibits the development and activation of osteoclasts (the cells that eat away bone). It is administered by an injection under the skin, twice yearly. Continue reading

Let BC PharmaCare hear “Your Voice” on certolizumab pegol

Megaphone GraphicBC PharmaCare is looking for your input on the subcutaneous injection of certolizumab pegol for the treatment of psoriatic arthritis

The subcutaneous (under the skin) injection certolizumab pegol (Cimzia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about certolizumab pegol for the treatment of psoriatic arthritis (PsA).

You can give input if you are a B.C. resident and have PsA, a caregiver to someone with PsA, or if your group represents people who live with PsA. Continue reading